Effect Of Recombinant Human Brain Natriuretic Peptide In Cardiac And Renal Function Of Patients With Type 1 And Type 2 Cardiorenal Syndrome

Objectives: This research retrospective investigated the relevant data of sufferers with Type 1 and Type 2 CRS,aiming to discuss the effect of rhBNP on cardiac function and renal function in sufferers with type 1 and Type 2 CRS.At the same time,the influence of urine output and blood pressure was discussed.Methods: From January 2018 to November 2020,the relevant information of 215 patients with type 1 and type 2 CRS who were hospitalized in our department and followed the relative standard were selected in this study.Among them,104 patients treated with rhBNP has been grouped as the test group,and 111 patients who had not been treated with rhBNP has been grouped as the comparison group.The basic information has been gathered in both groups,and the N-terminal pro-brain natriuretic peptide(NT-pro BNP)and left ventricular ejection fraction(LVEF),serum creatinine(Scr)and estimated glomerular filtration rate(e GFR),urine output and blood pressure were gathered before and after treatment.Finally,spss26.0 has been used for the data processing.Results:215 patients in the research conforms to the standard in all,including the rhBNP group 104 people and control group 111 people.The data of this two groups were contrasted as follows:(1)In basic information comparison,the age of rhBNP group were 74.47±14.72 years old,and the comparison group was 77.98±10.36 years old.There was no clear distinction in gender,cardiac function grade,ratio of underlying diseases,and ratio of other therapeutic drugs.(2)In the two groups after therapy,LVEF in the rhBNP group is higher than the control group(45.15±11.08%vs41.17±8.66%,P=0.002),the NT-pro BNP is lower than the control group(5133.25±5255.55 ng/L vs 7710.69±6950.97 ng/L,P=0.003),there are statistical differences.(3)After relative therapy,Scr in the rhBNP group is lower than the comparison group(130.22±46.91μmmol/L vs 145.07±45.41μmmol/L,P=0.019),the e GFR is higher than the control group(46.05±15.38 vs 40.35±12.91,P=0.030),there are statistical differences.(4)After relative therapy,the 24h urine volume in rhBNP group is more than the control group(1930.77±1062.76ml vs 1479.68±388.30ml,P=0.000),there are statistical differences.(5)After relative therapy,the systolic blood pressure in the rhBNP group is mildly less than the comparison group(112.25±14.85mm Hg vs 116.41±15.60mm Hg,P=0.047),the distinction in diastolic pressure(62.08±12.70 vs 63.56±10.44ml,P=0.353)is not statistically meaning.Conclusions: Compared with conventional treatment,the addition of rhBNP therapy was beneficial to the further amelioration of cardiac function,renal function in sufferers with Type 1 and Type 2 CRS,and increased 24 h urine output,and mildly reduced systolic pressure,however,the influence on diastolic blood pressure was not palpable.